Xigad 25 Tablet contains Empagliflozin 25 mg, an oral antihyperglycemic agent belonging to the class of sodium-glucose co-transporter 2 (SGLT2) inhibitors. It is primarily indicated for the management of type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control. Empagliflozin works by inhibiting SGLT2 in the proximal renal tubules, thereby reducing glucose reabsorption and increasing urinary glucose excretion, which leads to lowered plasma glucose levels. This mechanism also contributes to modest reductions in body weight and systolic blood pressure. Xigad 25 is typically administered once daily, with or without food, and dosage adjustments may be necessary based on renal function and clinical response. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal impairment, or hypersensitivity to the active substance. Common adverse effects include urinary tract infections, genital mycotic infections, and increased urination. Patients should be monitored for signs of volume depletion and electrolyte imbalances. Empagliflozin has also demonstrated cardiovascular benefits in patients with established cardiovascular disease, reducing the risk of cardiovascular death. As with all antidiabetic therapies, therapy with Xigad 25 should be individualized and combined with lifestyle modifications for optimal outcomes.